STOCK TITAN

AIM ImmunoTech Inc - AIM STOCK NEWS

Welcome to our dedicated news page for AIM ImmunoTech (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on AIM ImmunoTech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AIM ImmunoTech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AIM ImmunoTech's position in the market.

Rhea-AI Summary
AIM ImmunoTech Inc. (NYSE American: AIM) reported financial results for Q3 2023 and provided a business update, highlighting progress in the Ampligen® clinical development programs. The company aims to achieve value-driving milestones in ovarian and pancreatic cancer programs. Recent highlights include encouraging translational data from an ongoing Phase 2 clinical trial in ovarian cancer and engaging a business development consulting firm to partner pipeline programs. Financially, AIM reported $22.4 million in cash, with increasing R&D and G&A expenses. The company will host a conference call and webcast on November 15, 2023, to discuss operational and financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
earnings
-
Rhea-AI Summary
AIM ImmunoTech Inc. (NYSE American: AIM) announces the publication of results from the Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple-negative breast cancer using chemokine modulation therapy. The study evaluated the safety and the combination's ability to promote local CTL influx to mTNBC lesions. The data were published in The Journal for ImmunoTherapy of Cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
clinical trial
-
Rhea-AI Summary
AIM ImmunoTech Inc. (AIM) to host conference call to discuss Q3 2023 operational and financial results. Interested participants and investors can access the call and webcast on November 15, 2023. The call will feature AIM's CEO and Scientific Officer, providing insights into the company's performance and future prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.51%
Tags
earnings
Rhea-AI Summary
AIM ImmunoTech Inc. (NYSE American: AIM) announced encouraging translational data from an ongoing Phase 2 clinical trial utilizing AIM’s drug Ampligen® in patients with platinum-sensitive advanced recurrent ovarian cancer. The data highlights the effectiveness of combinatorial treatments including Ampligen in modulating the cellular make-up of the tumor microenvironment through cytokine profile changes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
clinical trial
-
Rhea-AI Summary
AIM ImmunoTech Inc. has filed its Definitive Proxy Statement for the upcoming 2023 Annual Meeting of Stockholders. The company urges shareholders to vote for the Board of Directors and discard any proxy materials from the activist group. AIM has also launched www.SafeguardAIM.com to provide updates to shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
none
-
Rhea-AI Summary
AIM ImmunoTech Inc. announced that an abstract from the Magee-Womens Research Institute at the University of Pittsburgh School of Medicine has been accepted for presentation at the Society for Immunotherapy of Cancer Annual Meeting. The abstract focuses on a Phase 2 trial evaluating the combination of cisplatin, Ampligen, and pembrolizumab for patients with recurrent platinum-sensitive ovarian cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.98%
Tags
none
Rhea-AI Summary
AIM ImmunoTech partners with Azenova to explore partnership opportunities for its lead asset, Ampligen®, in the treatment of solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.87%
Tags
none
-
Rhea-AI Summary
AIM ImmunoTech Inc. announces Chris McAleer, Ph.D., to present at cancer research symposium and sponsorship of the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
conferences
-
Rhea-AI Summary
Complete topline results confirm promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic) at 66% in Phase 1 study of Ampligen for early-stage TNBC. Treatment was well-tolerated with mostly grade 1 or 2 TRAEs. Positive findings support continued development of Ampligen.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.62%
Tags
none
Rhea-AI Summary
AIM ImmunoTech to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
AIM ImmunoTech Inc

NYSE:AIM

AIM Rankings

AIM Stock Data

21.64M
44.36M
9.19%
8.52%
0.84%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Ocala

About AIM

aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as